H

Health Concepts | Rapid City, SD

Research site
(Unclaimed)
Location
5410 Sheridan Lake Road, Rapid City, South Dakota, United States of America
Site insights

Top conditions

Psoriasis (20 trials)

Atopic Dermatitis (17 trials)

Eczema (17 trials)

Dermatitis (17 trials)

Osteoarthritis (12 trials)

Top treatments

Relamorelin
Dupilumab
PF-06700841
PF-04965842
Olezarsen
Tanezumab
Hydrocodone Bitartrate
K-877
JNJ-77242113
ISIS 678354

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

19 of 93
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy (REGAiN-1B)

To evaluate the durability of efficacy and long-term safety of intramuscular (IM) administration of Engensis or Placebo that was administered in the...

Enrolling
Diabetic Peripheral Neuropathy
Biological: Engensis
Other: Placebo

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The coprimary objectives of the study are to:evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineu...

Enrolling
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Enrolling
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Enrolling
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

Enrolling
Severe Hypertriglyceridemia
Drug: Olezarsen

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from bas...

Enrolling
Severe Hypertriglyceridemia
Drug: Placebo
Drug: Olezarsen

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in particip...

Enrolling
Hypertriglyceridemia
Cardiovascular Diseases
Drug: Placebo
Drug: Olezarsen

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo
Locations recently updated

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Dupilumab

The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.

Active, not recruiting
Psoriasis
Other: Placebo
Drug: BMS-986322

The purpose of this study is to learn about the safety and effects of the study medicine called etrasimod for the possible treatment of atopic dermat...

Active, not recruiting
Atopic Dermatitis
Eczema, Atopic
Drug: etrasimod
Drug: Placebo

The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneous using devices for injection at home.

Enrolling
Atopic Dermatitis
Combination Product: Rocatinlimab Prefilled Syringe

A double-blind, randomized, placebo-controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of single injection of...

Active, not recruiting
Osteoarthritis
Drug: RTX-GRT7039
Drug: Placebo

This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to e...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: AR1001

Primary Objective:To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Inhaled Long-Acting Muscarinic Antagonist

The purpose of this study is to evaluate the efficacy and safety of intramuscular (IM) administration of Engensis on pain in participants with painfu...

Active, not recruiting
Diabetic Neuropathy, Painful
Other: Placebo
Biological: Engensis

Otherwise healthy index patients (IP) are randomized to either baloxavir marboxil or placebo if their influenza symptoms onset was within 48 hours of...

Enrolling
Influenza
Drug: Baloxavir Marboxil
Drug: Placebo

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 100 mg
Drug: Placebo

Trial sponsors

Pfizer logo

Pfizer (29 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems